Pharmaceutical

CymaBay seeks FDA approval for primary biliary cholangitis therapy

CymaBay Therapeutics has filed a new drug application (NDA) with the FDA seeking approval for seladelpar for PBC management.

Dec 18, 2023 - 10:51
CymaBay seeks FDA approval for primary biliary cholangitis therapy
CymaBay Therapeutics has filed a new drug application (NDA) with the FDA seeking approval for seladelpar for PBC management.
Read the original article

Tags:

Previous Article

Biocytogen and Ona enter cancer ADC development deal

Next Article

EMA CHMP recommends Takeda’s Hyqvia for CIDP treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: UHS finance chief said company favors patients whose insurance pays more

STAT+: UHS finance chief said company favors patients w...

Jul 26, 2023

EC upgrades approval for J&J’s Rybrevant/chemotherapy combination in NSCLC

EC upgrades approval for J&J’s Rybrevant/chemotherapy c...

Aug 29, 2024

STAT+: Here’s what you might have missed in Biden’s budget proposal

STAT+: Here’s what you might have missed in Biden’s bud...

Mar 13, 2024